ClinicalTrials.gg
CompletedNCT01929876Updated Aug 4, 2016Results posted

A Study to Evaluate Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Participants

A Phase 1 interventional study of Cobimetinib and Itraconazole in Healthy Participants, sponsored by Genentech, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-04.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This open-label, 2-period, fixed sequence, drug interaction study will investigate the effect of co-administration of itraconazole on the pharmacokinetics of cobimetinib in healthy participants. Participants will receive multiple repeating doses of cobimetinib and itraconazole.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult participants
  • Within (BMI) range 18.5 to 32 kilogram per meter square (kg/m\^2), inclusive
  • Creatine phosphokinase levels below 2.5 times the (ULN) and if elevated, not
  • Liver function tests for , alanine aminotransferase, and alkaline phosphatase below 2 times the ULN; below 1.5 times the ULN; and all liver function test elevations not clinically significant
  • In good health, determined by no clinically significant findings from medical history, 12-lead (ECG), and vital signs
  • Clinical laboratory evaluations within the reference range for the test laboratory, unless deemed not clinically significant by the Investigator
  • Negative test for selected drugs of abuse at screening and at each check-in
  • Negative hepatitis panel (including surface antigen [HBsAg] and anti- virus [HCV]) and negative (HIV) antibody screens
  • Females non-pregnant or non-lactating
  • Males and females (of ) to use two forms of adequate

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs; except that appendectomy, hernia repair, and/or cholecystectomy will be allowed
  • History of diabetes mellitus and/or elevated fasting glucose at baseline
  • History or presence of an abnormal , which in the Investigator's opinion, is
  • History of alcoholism or drug addiction within 1 year prior to study start
  • Use of any tobacco- or nicotine-containing products (within 6 months prior to study start and during the entire study
  • Participation in any other study or biologic agent trial in which receipt of an investigational study drug occurred within 5 half-lives or 30 days, whichever is longer, or exposure to any biological therapy or investigational biological agent within 90 days prior to study entry and during the entire study from study start to study completion, inclusive
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Cobimetinib + Itraconazole

    Drug: Cobimetinib · Drug: Itraconazole

Interventions

  • 10 milligram (mg) (2\* 5 mg capsules) will be administered orally on Day 1 of Period 1 and Day 4 of Period 2

    Also known as: GDC-0973

  • 200 mg oral solution will be administered once daily from Day 1 to Day 14 of Period 2

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Cobimetinib With and Without Itraconazole

    Maximum observed plasma concentration of cobimetinib with and without itraconazole was assessed using a model independent approach.

    Time frame: Period 1: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192 hours postdose on Day 1; Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4

  2. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - Inf)] of Cobimetinib With and Without Itraconazole

    AUC (0 - inf) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf) of cobimetinib with and without itraconazole, assessed using a model independent approach.

    Time frame: Period 1: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192 hours postdose on Day 1; Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4

Secondary outcomes

  1. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Cobimetinib With and Without Itraconazole

    Time to reach maximum observed plasma concentration of cobimetinib with and without itraconazole was assessed using a model independent approach.

    Time frame: Period 1: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192 hours postdose on Day 1; Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4

  2. Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Cobimetinib With and Without Itraconazole

    AUC (0-t) = Area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (0-t) of cobimetinib with and without itraconazole was assessed. It was calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic rule for decreasing concentrations using a model independent approach.

    Time frame: Period 1: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192 hours postdose on Day 1; Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4

  3. Plasma Half-Life (t1/2) of Cobimetinib With and Without Itraconazole

    Plasma half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Period 1: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192 hours postdose on Day 1; Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4

  4. Apparent Clearance (CL/F) of Cobimetinib With and Without Itraconazole

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated using a model independent approach.

    Time frame: Period 1: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192 hours postdose on Day 1; Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4

  5. Apparent Volume of Distribution (Vz/F) of Cobimetinib With and Without Itraconazole

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction of drug absorbed.

    Time frame: Period 1: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192 hours postdose on Day 1; Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4

  6. Cmax of Itraconazole and Hydroxy-Itraconazole

    Maximum observed plasma concentration of itraconazole and its metabolite hydroxy-itraconazole was assessed using a model independent approach.

    Time frame: Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4

  7. Tmax of Itraconazole and Hydroxy-Itraconazole

    Time to reach maximum observed plasma concentration of itraconazole and its metabolite hydroxy-itraconazole was assessed using a model independent approach.

    Time frame: Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4

  8. Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] of Itraconazole and Hydroxy-Itraconazole

    AUC (0-24) = Area under the plasma concentration versus time curve from time zero (predose) to 24 hours postdose (0-24) of itraconazole and its metabolite hydroxy-itraconazole was assessed using a model independent approach.

    Time frame: Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24 hours post cobimetinib dose on Day 4

07

Results

Posted Aug 4, 2016

Participant flow

Period 1
Participant flow — Period 1
MilestoneCobimetinib + Itraconazole
Started16
Completed16
Not completed0
Period 2
Participant flow — Period 2
MilestoneCobimetinib + Itraconazole
Started16
Completed15
Not completed1
Withdrew: Non-compliance1

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Cobimetinib With and Without Itraconazole

Maximum observed plasma concentration of cobimetinib with and without itraconazole was assessed using a model independent approach.

Time frame:
Period 1: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192 hours postdose on Day 1; Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Cobimetinib With and Without Itraconazole
nanogram per milliliter (ng/mL)Cobimetinib + Itraconazole
Period 1: Cobimetinib Alone5.21 ± 38.1
Period 2: Cobimetinib With Itraconazole16.5 ± 27.7
Statistical analysis
  • Cobimetinib + Itraconazole · Ratio of least squares means: 316.6 · 90% CI 268.1 to 374.0LS means from analysis of variance (ANOVA), calculated by transforming the natural log means back to the linear scale (that is, geometric LS mean).
PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - Inf)] of Cobimetinib With and Without Itraconazole

AUC (0 - inf) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf) of cobimetinib with and without itraconazole, assessed using a model independent approach.

Time frame:
Period 1: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192 hours postdose on Day 1; Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - Inf)] of Cobimetinib With and Without Itraconazole
ng*hr/mLCobimetinib + Itraconazole
Period 1: Cobimetinib Alone (n=14)241 ± 51.5
Period 2: Cobimetinib With Itraconazole (n=12)1596 ± 23.0
Statistical analysis
  • Cobimetinib + Itraconazole · Ratio of ls means: 672.3 · 90% CI 563.7 to 801.9Ratio of LS means (Cobimetinib with Itraconazole/Cobimetinib alone) of natural log-transformed parameter (expressed as a percent). LS means from ANOVA, calculated by transforming the natural log means back to the linear scale.
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Cobimetinib With and Without Itraconazole

Time to reach maximum observed plasma concentration of cobimetinib with and without itraconazole was assessed using a model independent approach.

Time frame:
Period 1: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192 hours postdose on Day 1; Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Cobimetinib With and Without Itraconazole
hoursCobimetinib + Itraconazole
Period1: Cobimetinib Alone2.00 (1.00 to 6.05)
Period 2: Cobimetinib With Itraconazole4.00 (2.00 to 8.02)
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Cobimetinib With and Without Itraconazole

AUC (0-t) = Area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (0-t) of cobimetinib with and without itraconazole was assessed. It was calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic rule for decreasing concentrations using a model independent approach.

Time frame:
Period 1: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192 hours postdose on Day 1; Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Cobimetinib With and Without Itraconazole
nanogram*hour per milliliter (ng*hr/mL)Cobimetinib + Itraconazole
Period 1: Cobimetinib Alone209 ± 49.4
Period 2: Cobimetinib With Itraconazole1220 ± 24.0
Statistical analysis
  • Cobimetinib + Itraconazole · Ratio of ls means: 583.9 · 90% CI 488.2 to 698.2Ratio of LS means (Cobimetinib with Itraconazole/Cobimetinib alone) of natural log-transformed parameter (expressed as a percent). LS means from ANOVA, calculated by transforming the natural log means back to the linear scale.
SecondaryPlasma Half-Life (t1/2) of Cobimetinib With and Without Itraconazole

Plasma half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Period 1: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192 hours postdose on Day 1; Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4
Reported as:
Median · hours
Plasma Half-Life (t1/2) of Cobimetinib With and Without Itraconazole
hoursCobimetinib + Itraconazole
Period1: Cobimetinib Alone (n=14)58.6 (25.9 to 89.2)
Period 2: Cobimetinib With Itraconazole (n=12)118 (83.1 to 170)
SecondaryApparent Clearance (CL/F) of Cobimetinib With and Without Itraconazole

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated using a model independent approach.

Time frame:
Period 1: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192 hours postdose on Day 1; Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4
Reported as:
Geometric mean · liter per hour (L/hr)
Apparent Clearance (CL/F) of Cobimetinib With and Without Itraconazole
liter per hour (L/hr)Cobimetinib + Itraconazole
Period1: Cobimetinib Alone (n=14)41.4 ± 51.5
Period 2: Cobimetinib With Itraconazole (n=12)6.27 ± 23.0
SecondaryApparent Volume of Distribution (Vz/F) of Cobimetinib With and Without Itraconazole

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction of drug absorbed.

Time frame:
Period 1: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192 hours postdose on Day 1; Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4
Reported as:
Geometric mean · liter (L)
Apparent Volume of Distribution (Vz/F) of Cobimetinib With and Without Itraconazole
liter (L)Cobimetinib + Itraconazole
Period1: Cobimetinib Alone (n=14)3233 ± 27.5
Period 2: Cobimetinib With Itraconazole (n=12)1065 ± 36.1
SecondaryCmax of Itraconazole and Hydroxy-Itraconazole

Maximum observed plasma concentration of itraconazole and its metabolite hydroxy-itraconazole was assessed using a model independent approach.

Time frame:
Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4
Reported as:
Geometric mean · ng/mL
Cmax of Itraconazole and Hydroxy-Itraconazole
ng/mLCobimetinib + Itraconazole
Itraconazole1480 ± 42.6
Hydroxy-Itraconazole1243 ± 26.4
SecondaryTmax of Itraconazole and Hydroxy-Itraconazole

Time to reach maximum observed plasma concentration of itraconazole and its metabolite hydroxy-itraconazole was assessed using a model independent approach.

Time frame:
Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 192, 240 hours post cobimetinib dose on Day 4
Reported as:
Median · hours
Tmax of Itraconazole and Hydroxy-Itraconazole
hoursCobimetinib + Itraconazole
Itraconazole2.00 (1.00 to 24.0)
Hydroxy-Itraconazole4.00 (2.00 to 6.00)
SecondaryArea Under the Curve From Time Zero to 24 Hours [AUC (0-24)] of Itraconazole and Hydroxy-Itraconazole

AUC (0-24) = Area under the plasma concentration versus time curve from time zero (predose) to 24 hours postdose (0-24) of itraconazole and its metabolite hydroxy-itraconazole was assessed using a model independent approach.

Time frame:
Period 2: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 12, 24 hours post cobimetinib dose on Day 4
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] of Itraconazole and Hydroxy-Itraconazole
ng*hr/mLCobimetinib + Itraconazole
Itraconazole15607 ± 26.8
Hydroxy-Itraconazole23176 ± 23.2

Adverse events

Collected over approximately 2 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cobimetinib + Itraconazole—0/16 (0%)6/16 (37.5%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCobimetinib + Itraconazole
Abdominal painGastrointestinal disorders1/16
DiarrhoeaGastrointestinal disorders1/16
DyspepsiaGastrointestinal disorders1/16
ErythemaSkin and subcutaneous tissue disorders1/16
Rash macularSkin and subcutaneous tissue disorders1/16
Alanine aminotransferase increasedInvestigations1/16
Aspartate aminotransferase increasedInvestigations1/16
DizzinessNervous system disorders1/16
HeadacheNervous system disorders1/16
RhinitisInfections and infestations1/16

Baseline characteristics

Safety population consisted of all participants who received at least 1 dose of cobimetinib and had at least 1 postdose safety assessment.

Age, Continuous
Age, Continuous(years)Cobimetinib + Itraconazole
Mean38 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Cobimetinib + Itraconazole
Female5
Male11
08

Study locations

1 site
  • Dallas, Texas 75247, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2013
First posted
Aug 28, 2013
Start
Jul 2013
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Aug 4, 2016
Last update
Aug 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01929876
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Aug 28, 2013
Start date
Jul 2013
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Aug 4, 2016
Last update
Aug 4, 2016

Study contacts

Clinical Trials
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cobimetinib

Start the discussion